Innovimmune’s INV-71 program targets ROR gamma, a master control switch of immune system activation. This novel therapeutic approach combines multiple anti-tumor mechanisms with a single agent NME promoting anti-tumor immunity through RORg agonism. It has potential as a monotherapy, and in combination with novel immunotherapies including adoptive cell therapies. RORg activation with INV-71 would be expected to provide a superior safety profile associated with the absence of generalized immunosuppression; minimal off-target and on-target toxicities.

The INV-71 program is currently being fast-tracked for Entry into IND-enabling development for several solid tumors. The preclinical POC efficacy of immuno-oncologic clinical therapeutic INV-71 candidate drugs as mono-therapy and in combination with other immunotherapies have recently been established.